Boardroom Alpha
Boardroom Alpha
ABOS · Additional Proxy Materials (DEFA14A) · Filed April 23, 2026

Acumen Pharmaceuticals Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 23, 2026
Ticker
ABOS
Accession
0001628280-26-026871
Boardroom Alpha · Filing insights

Acumen Pharmaceuticals' board urges stockholders to vote FOR all nominees and Proposals 2 and 3.

About Acumen Pharmaceuticals Inc
Market cap
$171M
1Y TSR
+113.4%
3Y TSR
−22.4%
Board grade
C
Sector
Healthcare
CEO
Daniel Joseph Oconnell
Last annual meeting: Jun 3, 2026 · View full Acumen Pharmaceuticals Inc profile →
DEFA14A2026

SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:
oPreliminary Proxy Statement
oConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
oDefinitive Proxy Statement
xDefinitive Additional Materials
oSoliciting Material Pursuant to § 240.14a-12
Acumen Pharmaceuticals, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
xNo fee required.
oFee paid previously with preliminary materials
oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


Your control number Your vote matters! Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 3, 2026 for Stockholders of Record as of April 8, 2026 To order paper materials, use one of the following methods. Internet: www.investorelections.com/ABOS Call: 1-866-648-8133 Email: paper@investorelections.com * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved Acumen Pharmaceuticals, Inc. Annual Meeting of Stockholders Wednesday, June 3, 2026 11:00 AM, Eastern Time Annual meeting to be held virtually via the internet - please visit www.proxydocs.com/ABOS for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/ABOS To view the proxy materials (including the proxy statement and annual report), VOTE, and obtain directions to attend the meeting, go to www.proxydocs.com/ABOS. To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper form. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 25, 2026. styleINA P.O. BOX 8016, CARY, NC 27512-9903 SEE REVERSE FOR FULL AGENDA


 
PROPOSAL 1. To elect three Class II directors to the Board of Directors, each to hold office until the 2029 Annual Meeting of Stockholders, and until his or her successor shall have been duly elected and qualified. 1.01 George Golumbeski, Ph.D. 1.02 Derrell Porter, M.D. 1.03 Laura Stoppel, Ph.D. 2. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. 3. To approve the Company's Amended and Restated 2021 Equity Incentive Plan. 4. To conduct any other business properly brought before the meeting or any adjournments, continuations, or postponements thereof. THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR EACH OF THE NOMINEES FOR DIRECTOR IN PROPOSAL 1, FOR PROPOSAL 2 AND FOR PROPOSAL 3 Acumen Pharmaceuticals, Inc. Annual Meeting of Stockholders


 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Acumen Pharmaceuticals Inc (ABOS)

Reference

Frequently asked questions

When did Acumen Pharmaceuticals Inc file this DEFA14A?
Acumen Pharmaceuticals Inc (ABOS) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 23, 2026. The accession number assigned by EDGAR is 0001628280-26-026871.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Acumen Pharmaceuticals' board urges stockholders to vote FOR all nominees and Proposals 2 and 3. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Acumen Pharmaceuticals Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Acumen Pharmaceuticals Inc has filed under CIK 1576885, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer